

ONCOLOGY

The ACM Approach
to Smarter Testing™
for Oncology

ACM
GLOBAL LABORATORIES



THINKING THERAPEUTICALLY

WE'VE TAKEN OUR SMARTER TESTING APPROACH TO
CLINICAL TRIALS TESTING AND COMBINED IT WITH OUR
EXTENSIVE EXPERTISE IN ONCOLOGY TO DELIVER A
UNIQUE SERVICE OFFERING FOR CANCER RESEARCH.

What You Can Expect from Our Smarter Testing for Oncology:

- Access to scientific experts and a growing network of subspecialty pathologists
- An extensive oncology testing menu
- A continuous commitment to state-of-the-art image analytics for more accurate and objective quantitative results
- A consultative approach to identifying endpoints and selecting the appropriate mix of tests to achieve the desired outcomes

THIS IS SMARTER TESTING.

Access to Subspecialty Expertise

The current global shortage of anatomic pathologists is expected to worsen over the next five years, and as a result, many oncology trials face the challenging task of finding adequate pathology services for their studies.

- As an affiliate company of Rochester Regional Health (RRH), ACM offers access to a staff of more than 20 in-house pathologists, as well as a growing network of subspecialty pathologists and practicing oncologists. Our clients have access to a unique mix of cancer treatment experts who regularly collaborate on study design. Whether you need a dermatopathologist or a hematopathologist, ACM offers a wide range of general and subspecialty services in surgical pathology, cytopathology, and clinical pathology. Our expert pathology staff is continually engaged in clinical trial studies each year and has a strong understanding of the data collection and reporting needs of clinical trial clients.

PATHOLOGY EXPERTISE

Oncologic Pathology

Gastrointestinal

Breast

Hepatobiliary

Gynecologic

Hematopathology

Dermatopathology

Urologic

Placenta and Perinatal

Bone and Soft Tissue

ACM
GLOBAL LABORATORIES

Our pathologists cover a hospital system that is responsible for more than 98,000 surgical pathology specimens and over 60,000 cytology specimens a year. As a result, our pathologists regularly see and handle a large number of complex cases.

Extensive Oncology Test Menu Includes the Latest in Biomarker Testing

We have a comprehensive offering of in-house ancillary testing that includes flow cytometry, in-situ hybridization and immunohistochemistry and maintain strategic relationships with leading reference laboratories to offer the full gamut in cutting-edge oncologic testing. Through our in-house offerings and our partnerships with leading reference labs, we can offer clients a broad array of testing to meet their study needs and offer expert interpretation of nearly every type of tissue or fluid specimen encountered in research or clinical practice.

Areas of clinical trial and clinical practice expertise:

- Anal Pap Tests
- Bone & Soft Tissue
- Dermatopathology
- Forensic Pathology
- Gastrointestinal
- Gynecologic
- Hematopathology
- Hepatobiliary
- Non-Gynecologic Specimens from all body sites
- Oncologic
- Pap smears and fluid-based (ThinPrep) pap specimens
- Placental & Perinatal
- Routine Autopsy Work
- Toxicology
- Urologic

State-of-the-art Image Analytics for Quicker Turnarounds and More Accurate Quantitative Data

We've embraced whole slide imaging technology and tumor cell detection and biomarker quantification software for more accurate and objective quantitative results.

- Leica Biosystems' Aperio AT2 whole slide scanner expands upon the anatomic pathology testing performed at ACM, while increasing our ability to scale pathology resources for sponsors and CROs conducting global oncology trials. In addition, we can send precise electronic slides that are available for remote viewing in less than a minute and apply computer algorithms to digitized slides to assist pathologists in the identification of areas of interest or in automatically scoring the positivity of various immunohistochemical stains.
- Visiopharm's tumor cell detection and biomarker quantification software provides objective cell counts such as the exact number of inflammatory cells in a biopsy, or the proportion of tumor cells to normal cells. These objective results are frequently helpful in aiding investigators reach statistical significance in their studies.



Our Smarter Approach to Oncology

Sponsors are under pressure to collect greater amounts of data, while indications for novel therapeutics continue to become more targeted. This focus on targeted therapy in oncology drug development requires sponsors to identify specific endpoints that put more emphasis on esoteric laboratory tests. In some cases, however, those tests can yield redundant or potentially contradictory results.

At ACM, we advocate an outcomes-based approach to clinical trials testing, where desired study outcomes are achieved by identification of endpoints and associated laboratory testing to achieve those outcomes. Our scientific experts understand the multitude of tests available and work with you to determine how to best apply them to the outcomes you seek. Working with our in-house pathologists, who are available for consult from the onset, we help tailor the testing according to the study endpoints. By determining the classification of the cancer, understanding the variants in the patient and the effectiveness of a drug on a particular tumor and the markers or stains being looked at, we're able to not only ensure the most appropriate tests are chosen for the desired outcome, but that critical milestones in the trial are feasible.

A Long History in Cancer Research

The blockbuster drug model has proven challenging to sustain. Sponsors and CROs have increasingly had to take more proactive measures to optimally position their clinical trials for success and to gain a competitive advantage in introducing new drugs to the market. Oncology trials have seen an increased focus on molecular genetics and matching diagnostics to specific genotypes and disease subtypes. With new types of testing, specific biomarkers and companion diagnostics playing a key role in supporting highly targeted therapeutics and precision medicine, engaging a central lab with extensive oncology experience early in the protocol development process has never been more crucial.

A photograph of two female scientists in a laboratory. They are both wearing white lab coats. The scientist on the right is holding a tablet and pointing at the screen with her right hand. The scientist on the left is also pointing at the screen with her right hand. They are standing in front of a laboratory bench with various pieces of equipment, including a large white machine with a screen and a microscope. The background shows large windows and a clean, professional laboratory environment. The entire image has a blue overlay with a pattern of white circles and lines.

Experience How our Smarter Testing Can Optimize
Your Outcomes in Oncology Research.

Call us at +1-866-405-0400 or visit bit.ly/ACM-oncology
to see how we can address your oncology testing needs.

ACM
GLOBAL LABORATORIES

ACM Global Lab, Americas
Rochester, New York, USA

ACM Global Lab, Europe
York, United Kingdom

ACM Global Lab, Singapore
Singapore

ACM Global Lab, China
Shanghai, China

ACM Global Lab, India
Mumbai, India

ACM
GLOBAL LABORATORIES

www.acmgloballab.com

www.acmgloballab.com • 1-866-405-0400